Lupin Q2 net profit up 24% at Rs 266.9 cr
Net sales grew by 23.57% to Rs 1,741.7 crore during the second quarter from Rs 1,409.4 cr in the same period last fiscal.
By PTI | Updated:
NEW DELHI: Drug firm Lupin today said its consolidated net profit rose by 24.13 per cent to Rs 266.9 crore in the second quarter ended September 30, on the back of robust sales growth across all the geographies, including the US and Japan.
The company had posted a net profit of Rs 215 crore for the same period last fiscal, Lupin said in a statement.
Net sales of the company grew by 23.57 per cent to Rs 1,741.7 crore during the second quarter from Rs 1,409.4 crore in the same period last fiscal.
Commenting on the results, Lupin Ltd Managing Director Kamal K Sharma said: "We had a very good second quarter. Steady product approvals, launches and growth across the US, Europe, Japan and India have helped us deliver 25 quarters of consistent growth."
On a standalone basis, the company posted a net profit of Rs 268.12 crore, compared to Rs 162.39 crore in the same period last fiscal.
The Mumbai-headquartered firm's formulation sales in the US and EU grew by 16 per cent to Rs 598.1 crore in the second quarter from Rs 516.1 crore in the same period last fiscal.
During the second quarter, revenues from the company's India business grew by 22 per cent to Rs 512 crore from Rs 419.1 crore in the same period last fiscal.
The revenues of Lupin's Japanese subsidiary, Kyowa, grew by 14 per cent to Rs 178 crore in the second quarter and accounted for 10 per cent of the company's overall topline during the quarter.
In a similar fashion, the revenues of the company's South African subsidiary, Pharma Dynamics, rose by 61 per cent to Rs 67.9 crore in the second quarter from Rs 42.2 crore in the same period last fiscal.
During the quarter, the company's net sales from active pharmaceutical ingredients (API) rose to Rs 197.6 crore from Rs 195.1 crore in the same period last fiscal.
Meanwhile, in a separate filing to the BSE, the company said K V Kamath has resigned from the directorship of the company with effect from today.
Shares of Lupin closed at Rs 475 on the BSE, down 1.22 per cent from their previous close.
The company had posted a net profit of Rs 215 crore for the same period last fiscal, Lupin said in a statement.
Net sales of the company grew by 23.57 per cent to Rs 1,741.7 crore during the second quarter from Rs 1,409.4 crore in the same period last fiscal.
Commenting on the results, Lupin Ltd Managing Director Kamal K Sharma said: "We had a very good second quarter. Steady product approvals, launches and growth across the US, Europe, Japan and India have helped us deliver 25 quarters of consistent growth."
On a standalone basis, the company posted a net profit of Rs 268.12 crore, compared to Rs 162.39 crore in the same period last fiscal.
The Mumbai-headquartered firm's formulation sales in the US and EU grew by 16 per cent to Rs 598.1 crore in the second quarter from Rs 516.1 crore in the same period last fiscal.
ADVERTISEMENT
During the second quarter, revenues from the company's India business grew by 22 per cent to Rs 512 crore from Rs 419.1 crore in the same period last fiscal.
The revenues of Lupin's Japanese subsidiary, Kyowa, grew by 14 per cent to Rs 178 crore in the second quarter and accounted for 10 per cent of the company's overall topline during the quarter.
In a similar fashion, the revenues of the company's South African subsidiary, Pharma Dynamics, rose by 61 per cent to Rs 67.9 crore in the second quarter from Rs 42.2 crore in the same period last fiscal.
During the quarter, the company's net sales from active pharmaceutical ingredients (API) rose to Rs 197.6 crore from Rs 195.1 crore in the same period last fiscal.
ADVERTISEMENT
Meanwhile, in a separate filing to the BSE, the company said K V Kamath has resigned from the directorship of the company with effect from today.
Shares of Lupin closed at Rs 475 on the BSE, down 1.22 per cent from their previous close.
ADVERTISEMENT
Too busy to trade in stocks? Invest in Mutual Funds with ET Money!
Bookmark or read stories offline -
Download ET Markets APP
Download ET Markets APP
ADVERTISEMENT
